Description
DT-2216 is a proteolysis targeting chimera degrader which specifically targets Bcl-xL.
DT-2216
Product ID D760022
Cas No. 2365172-42-3
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 2365172-42-3 |
|---|---|
| Purity | ≥98% |
| Formula | C77H96ClF3N10O10S4 |
| Formula Wt. | 1542.36 |
| IUPAC Name | (2S,4R)-1-[(2S)-2-[[7-[4-[(3R)-3-[4-[[4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-(trifluoromethylsulfonyl)anilino]-4-phenylsulfanylbutyl]piperazin-1-yl]-7-oxoheptanoyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide |
| Synonym | DT2216 |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Negi A, Voisin-Chiret A. Strategies to reduce the on-target platelet toxicity of Bcl-xl inhibitors: PROTACs, SNIPERs, and prodrug-based approaches. Chembiochem. 2022 Jun 20;23(12):e202100689. PMID: 35263486
Shebl B, Ng D, Lalazar G, et al. Targeting BCL-XL in fibromellar hepatocellular carcinoma. JCI Insight. 2022 Sep 8;7(17):e161820. PMID: 36073545
Khan S, Wiegand J, Zhang P, et al. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol. 2022 Mar 9;15(1):23. PMID: 35260176
Thummuri D, Khan S, Underwood P, et al. Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216. Mol Cancer Ther. 2022 Jan;21(1):184-192. PMID: 34667112